Introduction
Testosterone and dihydrotestosterone, the two major natural androgens, exert their genotropic effects through the androgen receptor (AR) to have a primary role in reproduction and gender differentiation (Quigley et al., 1995) and also directly target non-reproductive tissues (Manolagas and Kousteni, 2001) . AR has been grouped with class I nuclear receptors (steroid receptors) that, upon ligand binding, typically dissociate from a cytosolic complex containing heat shock proteins, homodimerize and translocate into the nucleus (Pratt and Toft, 1997) and bind to inverted repeat DNA response elements in their target genes (Tsai and O'Malley, 1994; Beato et al., 1995) . The agonist bound receptors then recruit co-activators; in contrast, when bound to antagonists the receptors preferentially recruit corepressors (Glass and Rosenfeld, 2000; McKenna and O'Malley, 2002) . Class I nuclear receptors typically share a domain structure that includes a ligandindependent activation function 1 in the N-terminal domain, a ligand-dependent activation function 2, a DNA-binding domain and a C-terminal ligand-binding domain (Bourguet et al., 2000) . However, AR has several distinctive characteristics in its structural and functional organization compared with other steroid receptors (Jenster et al., 1995; Hong et al., 1996; Berrevoets et al., 1998; Gelmann, 2002; McEwan, 2004) , including its ability to bind as a homodimer to both direct and inverted repeat androgen response elements (AREs) (Shaffer et al., 2004) .
The action of AR is principally transcriptional (Gelmann, 2002; Xu et al., 2006) although some observations suggest a relatively minor contribution of cytosolic interactions of AR to cell survival Sun et al., 2003; Baron et al., 2004) . AR is required for the development, maintenance and function of the prostate (Roy et al., 1999) . It is also responsible for prostatic hyperplasia and malignancy and is expressed in most androgen-independent prostate tumors (Ruizeveld de Winter et al., 1994) in which it is believed to have a significant role in tumor growth and refractoriness to androgen ablation (Zegarra-Moro et al., 2002) . The exact mechanisms contributing to this androgen independence remain unclear, although AR gene amplification, AR mutations and an altered co-regulator complement as well as the phosphorylation or acetylation status of AR have been implicated (Miyamoto et al., 2004) . Genetic lesions that support androgen-independent prostate cancer growth, including activation of mitogen-activated protein kinase, phosphatidylinositol 3 kinase /AKT and protein kinase C pathways, converge on activation of AR (Edwards and Bartlett, 2005; Shand and Gelmann, 2006) . Cellular and molecular changes associated with androgen independence may also be expected to allow androgenindependent entry of AR into the nucleus. However, there is no clear evidence that, in truly hormonerefractory cells, hormone-independent transcriptional signaling by AR can occur through the classical DNA response elements (ARE) for AR; rather, in hormone refractory LNCaP prostate cancer cells, ARE-mediated gene activation was still ligand dependent, whereas AR supported hormone-independent growth by associating with target genes through other means (Jia and Coetzee, 2005 ; Gonit et al., publication pending); the putative tethered associations of AR with its target promoters have not been characterized.
In mammals, the CCAAT enhancer binding protein (C/EBP) family of homo-or hetero-dimeric basic/ leucine zipper transcription factors has at least six members designated a, b, g, d, e and z (Ramji and Foka, 2002) . The C/EBP element has a divergent dyad repeat sequence RTTGCGYAAY, in which R and Y represent A/G and C/T, respectively (Osada et al., 1996) . C/EBP family proteins are functionally coordinated in inducing the differentiation and function of several tissues (Ramji and Foka, 2002) ; however, in this context, C/EBPa has the unique role of inhibiting cell proliferation (Umek et al., 1991; Hendricks-Taylor and Darlington, 1995; Watkins et al., 1996) . C/EBPa also acts as a tumor suppressor (Watkins et al., 1996; Burel et al. 2001; Pabst et al., 2001a, b; Halmos et al., 2002; ; Gery et al., 2005; Schuster and Porse, 2006; Loomis et al., 2007) . The antiproliferative action of C/EBPa can occur independent of its ability to bind to DNA (Harris et al., 2001 ) by protein-protein interactions that include stabilization of p21 (Timchenko et al., 1996 (Timchenko et al., , 1997 , disruption of electro-acoustic 2 factor complexes (Timchenko et al., 1999a, b; Porse et al., 2001) , inhibition/degradation of cyclin-dependent kinases 2 and 4 (Wang et al., 2001 (Wang et al., , 2002 and interaction with the switch/sucrose nonfermentable chromatin remodeling complex (Muller et al., 2004) . In liver tumors, dephosphorylation of C/EBPa by activation of the phosphatidylinositol 3 kinase/AKT pathway abrogates its interactions with cyclin-dependent kinase 2 and electro-acoustic 2 factor complexes (Wang et al., 2004) ; dephosphorylated C/EBPa also promotes proliferation by sequestering retinoblastoma protein (Wang and Timchenko, 2005) .
CCAAT enhancer binding protein-a is expressed in prostate epithelial cells, entering the nucleus at the onset of maturation (Zhang et al., 2008) . Ectopic C/EBPa was antiproliferative in prostate cancer cells (Chattopadhyay et al., 2006) . Remarkably, C/EBPa is commonly expressed in malignant prostate tumors in which its relative levels correlate significantly with those of AR, especially in metastatic tumors, which express the highest levels (Yu et al., 2004; Zhang et al., 2008) , possibly reflecting functional modifications as noted above. In both normal and malignant prostate tissues, the function of C/EBPa also seems to be controlled through regulation of its nuclear-cytoplasmic distribution (Zhang et al., 2008) by mechanisms that are yet to be analysed.
When C/EBPa was ectopically expressed in cells that were C/EBPa negative, concomitant with growth inhibition, it bound to AR and inhibited ARE-mediated promoter activation by inhibiting co-activator recruitment (Chattopadhyay et al., 2006) . This finding has obvious physiological significance as androgen-stimulated growth must be attenuated at the late stages of formation of the prostate epithelium. However, as the principal physiological action of AR is believed to be genotropic, attenuation of its classical transcriptional activity by C/EBPa also poses the question of how AR can then support differentiation, maintenance and function of the prostate when C/EBPa is co-expressed. The issue led to the exploration of alternate promoter models to elucidate the nature and functional consequence of interaction between AR and C/EBPa. The studies reveal an alternate mechanism of interaction between AR and C/EBPa at C/EBPa-binding sites that could override the suppression of classical AR signaling by C/EBPa elsewhere in a gene and also enable AR to activate different genes. The novel mechanism has several remarkable features including ligand-independent promoter association and trans-activation per se under conditions that permit nuclear localization of AR and the absence of a need for AR dimerization. The bimodal interaction of AR and C/EBPa was extended to global gene regulation and chromatin associations in situ. The findings enable a comprehensive mechanistic understanding of the coordinated actions of AR and C/ EBPa in the normal prostate and reveal a potentially significant mechanism of AR signaling in hormonerefractory and anti-androgen-resistant prostate tumors.
Results
In contrast to prostate epithelial cells and clinical prostate tumors, established prostate cell lines have lost C/EBPa expression. Therefore, in the following experiments the role of endogenous C/EBPa was examined in HeLa cells, which express relatively low levels of C/EBPa. In LNCaP cells as well as in HeLa cells, C/EBPa was introduced ectopically to cover a range of expression levels.
Androgen receptor (AR) can be functionally recruited by DNA-bound CCAAT enhancer binding protein-a (C/EBPa) The possibility and functional consequence of recruitment of AR by DNA-bound C/EBPa on transcriptional activation of promoters was tested in two ways. First, a two-hybrid assay using Gal4 fusions of C/EBPa (amino acids 6-217) or C/EBPb (amino acids 1-256) and VP16-AR was used with a minimal promoter containing GAL4 elements (Figure 1a ). Both Gal4 fusion proteins produced basal trans-activation, but Gal4-C/EBPa mediated a striking increase in AR-specific transactivation by VP16-AR ( Figure 1a) ; in comparison, Gal4-C/EBPb only showed a modest effect (Figure 1a) . Second, the effect of C/EBPa or C/EBPb on testosterone/AR-dependent activation of an artificial minimal promoter-luciferase reporter construct containing three tandem C/EBP elements upstream of a TATA box ((C/EBP) 3 -TATA-Luc) was determined in ARtransfected HeLa cells; an identical promoter that did not contain the C/EBP elements (delC/EBP) was used as negative control (Figure 1b) . Testosterone/AR and C/EBP element-dependent activation of the promoter occurred in a manner that was further increased by ectopic C/EBPa but not C/EBPb (Figure 1b) . Thus, C/EBPa bound to its cognate element can recruit AR to positively regulate a minimal promoter.
Trans-activation by androgen receptor (AR) is supported by endogenous CCAAT enhancer binding protein-a (C/EBPa) and by AR co-activators The role of endogenous C/EBPa expressed in HeLa cells in mediating trans-activation by AR was tested by examining the effect of knocking down C/EBPa on ARdependent activation of the (C/EBP) 3 -TATA-Luc promoter ( Figure 1c ). Expression of AR was unaffected by knocking down C/EBPa, and AR did not alter the expression of endogenous C/EBPa (data not shown). The negative effect of knocking down C/EBPa on the testosterone/AR response of the promoter (Figure 1c) shows the role of endogenous C/EBPa in this regulation.
The effect of representative AR co-activators on the novel C/EBPa-dependent trans-activation by AR was examined (Figure 1d ). The prostate-specific antigen (PSA) promoter (ARE-driven control) and the (C/EBP) 3 -TATA promoter were tested; in both cases, CREB-binding protein and transcriptional intermediary factor 2 acted as activators of the testosterone/AR response. Furthermore, knocking down CREB-binding protein expression virtually completely abrogated the activation of both promoters (Figure 1e ). These results indicate co-activator dependence of the transcriptional activity of AR mediated through recruitment by C/EBPa. C/EBPa has opposite but independent effects on C/EBP element versus ARE-targeted promoter activation by AR Physical association with C/EBPa has been reported to inhibit promoter activation by AR in the context of the DNA (ARE)-bound receptor, that is, C/EBPa is a corepressor of AR in this context. The observation was confirmed for the PSA promoter in transfected HeLa cells in which ectopic C/EBPa and, to a lesser extent, ectopic C/EBPb inhibited the promoter activation by testosterone/AR in a dose-dependent manner (Figure 2a, top panel) . Under identical conditions, C/EBPa caused a striking dose-dependent increase in the activation of the (C/EBP) 3 -TATA promoter by AR; C/EBPb produced a similar effect but to a relatively modest extent (Figure 2a, bottom panel) . When, in a minimal promoter containing an ARE, a canonical C/EBP element was inserted upstream of the ARE, ectopic C/EBPa caused an increase in promoter activation by testosterone/AR (Figure 2b) . The results show that the interaction of C/EBPa and AR at a canonical C/EBP element, which result in trans-activation, overrides the inhibitory interaction of the two proteins at AREs elsewhere in the promoter.
Trans-activation per se by androgen receptor-CCAAT enhancer binding protein-a (AR-C/EBPa) occurs without androgen-dependence or sensitivity to flutamide As observed in Figure 1 , AR recruitment by C/EBPa and the associated trans-activation was only partially androgen dependent for wild-type AR. This could be explained by reported observations (Jenster et al., 1993) that in HeLa cells a substantial amount of ectopic AR can enter the nucleus independent of ligand and also hints that the primary role of androgen may be to further enhance nuclear translocation of AR in the transfected HeLa cells. To analyse this possibility, the intracellular localization of AR was examined using quantitative confocal microscopy in HeLa cells expressing different amounts of ectopic AR. In the absence of androgen treatment, the ectopic AR was localized in the nucleus as well as in the cytosol (Figure 3a) . Treatment with testosterone further mobilized the cytosolic AR to the nucleus (Figure 3a) . Under both conditions, the amount of AR in the nucleus was a function of the total AR expressed (Figure 3b) .
In HeLa cells, increasing expression levels of ectopic AR caused activation of the (C/EBP) 3 -TATA promoter by the receptor to become progressively androgen independent, both in the absence and in the presence of ectopic C/EBPa, reaching complete androgen independence at the highest level of AR (Figure 3c ). In contrast, under the same conditions, the AR activation of a promoter dependent entirely on AREs (the PSA promoter, Figure 3d ) was predominantly androgen dependent. In addition, the ARE-mediated promoter activation was sensitive to the androgen antagonist flutamide (Figure 3e ), whereas for C/EBP element-mediated activation insensitivity to flutamide accompanied androgen independence ( Figure 3e ). As shown in Figure 3b , as increasing the level of ectopic AR results in increased hormone-independent entry of AR into the nucleus, these results indicate that for C/EBP element-targeted promoter activation by AR, recruitment of AR to the promoter and trans-activation per se are independent of ligand. This conclusion is strongly supported by the contrasting observation that regardless of ectopic AR levels, ARE-mediated trans-activation required treatment with androgen. The principal role of androgen in C/EBP element-targeted promoter (a) The minimal promoter-luciferase reporter containing a GAL4 element (GAL4-TATA-Luc) was transfected into HeLa cells that were co-transfected with an expression plasmid for either VP16 or a VP16 fusion protein with AR (VP16-AR). The cells were additionally co-transfected with an expression plasmid for either Gal4 or the Gal4 fusion proteins, GAL4-C/EBPa(2-217) or GAL4-C/EBPb(1-256). The cells were treated with testosterone (10 nM) or vehicle for the duration of the transfection (48 h) after which they were subjected to luciferase assay. (b) The minimal promoter-luciferase reporter containing 3-tandem C/EBP elements ((C/EBP) 3 -TATA-Luc) or the same construct, in which the C/EBP elements were absent (delC/EBP-TATA-Luc), was transfected into HeLa cells with the co-transfection of AR plasmid or empty vector and C/EBPa expression plasmid, C/EBPb expression plasmid or empty vector. The cells were treated with testosterone (10 nM) or vehicle as described for panel a and harvested either to measure luciferase activity or for western blot analysis using antibody to AR, C/EBPa, C/EBPb or the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) loading control. (c) HeLa cells were transfected with C/EBPa small interfering RNA (siRNA) or negative control siRNA. The cells were co-transfected with combinations of AR expression plasmid (or vector) and (C/EBP) 3 -TATA-Luc reporter as indicated. Cells were treated with testosterone (10 nM) or vehicle for the duration of the transfection (48 h) and harvested either to measure luciferase activity or C/EBPa mRNA level. The mRNA level for C/EBPa is shown on the x axis as a ratio to the value for the control siRNA transfected samples. The expression of AR and treatment with testosterone had no significant effect on the C/EBPa mRNA level; conversely, the siRNA did not affect expression of AR (data not shown). The standard error in determining the C/EBPa mRNA level was o10%. (d) HeLa cells were separately transfected with two different promoter-luciferase constructs (prostate-specific antigen (PSA) Promoter-Luc or (C/EBP) 3 -TATA-Luc) and were co-transfected with an expression plasmid for AR together with the coactivator CREB-binding protein (CBP) or transcriptional intermediary factor 2 (TIF2) or with the vector control. The cells were treated with testosterone (10 nM) for the duration of the transfection (48 h) and harvested for luciferase assays. (e) HeLa cells were separately transfected with the two promoter-luciferase constructs used in (d) and were co-transfected with an expression plasmid for AR and either control siRNA or siRNA for CBP. The cells were treated with testosterone (10 nM) for the duration of the transfection (48 h) and harvested for luciferase assays. For (a-d), the P-values for the differences noted in the text were o0.001.
activation must thus be to enhance the localization of AR in the nucleus in the normal cell context, which limits androgen-independent entry of AR into the nucleus.
Multiple androgen receptor (AR) domains and a CCAAT enhancer binding protein-a (C/EBPa) peptide are involved in the association of AR with DNA-bound C/EBPa The specific AR domains required for interaction with C/EBPa in the context of AR recruitment by DNAbound C/EBPa was determined by a two-hybrid assay using Gal4-C/EBPa and N-terminal VP16 fusions of various AR domains. AR domains AB, CD, E and CDE showed variable but modest association with Gal4-C/ EBPa in comparison with the full-length VP16-AR ( Figure 4a ). The results indicate that in the context of DNA-bound C/EBPa, more than one AR domain must collectively contribute to the ability of the two proteins to associate. In similar two-hybrid assays, deletional analysis of GAL4-C/EBPa(6-217), which encompasses all of the activation domains of C/EBPa upstream of its conserved basic leucine zipper domain (Nerlov and Ziff, 1994) , showed that the C-terminal half of this polypeptide (amino acids 107-217) contains within it, the motif(s) required for binding to AR with most of the binding activity being dependent on the peptide 121-156 ( Figure 4b ). This peptide sequence spans one of three trans-activation elements of C/EBPa. Moreover, an internal deletion of peptide 146-156, as well as mutation of arginine at position 154 to alanine, strikingly decreased the ability of C/EBPa to support ARdependent promoter activation through the C/EBP element ( Figure 4c ), consistent with the importance of this region for binding to AR.
A dimerization mutant of androgen receptor (AR) interacts with CCAAT enhancer binding protein-a (C/EBPa) Deletion of amino acids 1 to 37 of AR (delAR(N)) did not significantly diminish association of the fusion protein with Gal4-C/EBPa ( Figure 4a ). As amino acids 3 to 36 are required for amino-to carboxyl-terminal (N-to C-) interaction of AR, which is believed to be responsible for the homodimerization of the receptor (Berrevoets et al., 1998) , it was of interest to examine the effect of the deletion on the association of AR with C/EBPa versus DNA sequence elements that make direct contact with AR. Accordingly, the effect of testosterone was tested in the two-hybrid assay using VP16-delAR(N) and Gal4-C/EBPa and was compared with the agonist effect in one-hybrid assays using the minimal Gal4 promoter in which the Gal4 element was replaced by a canonical ARE (Figure 5a ). Fusion with VP16 may be expected to allow AR to localize in the nucleus independent of ligand binding. Both VP16-AR and VP16-delAR(N) bound to Gal4-C/EBPa to the same extent with or without ligand ( Figure 4c ). In contrast, the binding of both VP16-AR and VP16-delAR(N) to ARE required agonist and further, the amino-terminal (1-37) deletion in AR partially reduced binding of the fusion protein to the ARE ( Figure 5a ); as observed in Figure 5b , this partial decrease is consistent with the partial loss of dimerization of VP16-AR with , the same promoter construct containing three-tandem C/EBP elements upstream of the ARE ((C/EBP) 3 -ARE-TATA-Luc) (bottom panel). The cells were cotransfected with AR expression plasmid or vector control, and C/EBPa expression plasmid or vector control. The cells were treated with testosterone and harvested for luciferase assays as described for panel a. For panels a and b, the P-values for the differences noted in the text were o0.001. the GAL4 fusion of the CDE domains of AR upon deletion of amino acids 1-37 (Figure 5b) .
The results show that whereas ligand-dependent dimerization of AR is essential for its interaction with a canonical ARE, recruitment of AR by DNA-bound C/EBPa can occur without AR dimerization. This observation is also consistent with the ability of DNAbound C/EBPa to recruit and mediate trans-activation by AR in the absence of androgen, which is required for AR dimerization.
CCAAT enhancer binding protein-a (C/EBPa) orchestrates global gene regulation by androgen receptor (AR) Affymetrix (Santa Clara, CA, USA) DNA microarray analysis was used to examine the genome-wide effect of C/EBPa on androgen signaling in LNCaP cells, which are deficient in C/EBPa. First, C/EBPa was introduced by transient transfection of an expression plasmid to minimize possible phenotypic alterations that might result from selection pressures in long-term cell culture 5 cells) or vector control and C/EBPa expression plasmid or vector. The cells were treated with testosterone (10 nM), vehicle or the combination of testosterone (10 nM) and flutamide (25 mM) for the duration of the transfection (48 h) and then harvested for luciferase assays. For panels b-e, the P-values for the differences noted in the text were o0.001. A full colour version of this figure is available at the Oncogene journal online.
C/EBPa and androgen receptor signaling J Zhang et al that would occur in the production of stable recombinant cells. The transfection efficiency for C/EBPa was B60%, as determined using flow cytometric analysis of co-expressed green fluorescent protein (data not shown). Ectopic expression of C/EBPa did not significantly alter the expression of endogenous AR and a 6-h treatment with the synthetic AR agonist R1881 (Dupont Inc., Wilmington, MA, USA) did not alter the expression of C/EBPa (Figure 6a) . The preceding mechanistic studies predict that the androgen responsiveness of genes may be differentially regulated by C/EBPa depending on the promoter contexts of the target genes; ARE-mediated gene activation would be inhibited by C/EBPa in one group of genes but in others C/EBPa may interact at other promoter sites to override this inhibition or even further increase transcriptional activation by AR. Consistent with this prediction, among genes that were activated (Xtwofold) by a 6-h treatment with R1881, the effect of ectopic C/EBPa on the androgen-stimulated mRNA expression ranged from a significant (B70%) inhibition to a further B2.5-fold activation (Figure 6c ; annotated data provided in Supplementary Table 1) .
Next, to identify genes whose induction was dependent on the presence of both AR signaling and C/EBPa, the mRNA profiles were examined in AR þ cells treated with R1881 or cells in which AR was completely knocked down ( Figure 6b) ; in both cases, the mRNA profiles were determined either in the absence or in the presence of ectopic C/EBPa. As predicted from the mechanistic studies, among genes that were unresponsive to AR signaling alone, many genes were synergistically activated by AR signaling and C/EBPa. The fold-change for AR and C/EBPa versus C/EBPa was adjusted to compensate for the fact that only B50% of the cells were transfected by the C/EBPa expression plasmid, as determined using co-transfected green fluorescent protein (data not shown). The list was filtered to remove all probe sets with activation by AR þ R1881/AR À control >1.2, those with average expression levels o64 and those with P-values for increase >0.01. The adjusted increases for the 100 genes with the greatest increases are plotted in Figure 6d (annotated data provided in Supplementary Table 2) .
To examine their potential mechanisms of regulation, the top 100 genes showing C/EBPa-dependent AR activation (from Supplementary Table 2) were submitted to the promoter analysis pipeline program (http:// bioinformatics.wustl.edu/webTools/PromoterSearch.do). This program reports enrichment for predicted binding sites for transcription factors in the promoter regions (À10 kb to þ 5 kb) of sets of genes. The submitted list of 100 genes matched 87 genes in the promoter analysis pipeline database. C/EBP sites were the top three highest scoring sites, with the lowest P-value of 0.2156, which from our experience indicates highly significant enrichment. For comparison, the top 100 genes whose expression increased in C/EBPa-transfected cells lacking AR, as compared with controls lacking AR, showed enrichment for C/EBP sites with a lowest P-value of 0.1852. Genes with adjusted values of C/EBPa-dependent AR activation o1.8-fold showed only marginal enrichment for C/EBP sites (data not shown).
Whereas regulation of any individual gene by AR and C/EBPa may be influenced or determined by additional factors related to their unique and complex promoter contexts, gene expression profiling presents a scenario for the physiological relevance of the bimodal regulation of AR signaling by C/EBPa elucidated in the preceding sections.
CCAAT enhancer binding protein-a (C/EBPa) induces functional chromatin associations of androgen receptor (AR) in situ Direct evidence for C/EBPa-dependent recruitment of AR at chromatin sites in situ was sought using chromatin immunoprecipitation-DNA microarray chip (ChIP-chip) analysis. Functional AREs are believed to generally map to chromatin sites distal (>10 kb) from their target promoters (Wang et al., 2007) , although association of those sites with the relevant target genes has only been made in a few cases. However, this study sought a more limited analysis of the genome to explore a significant presence of chromatin sites of C/EBPadependent AR recruitment. Accordingly, the RocheNimblegen (Madison, WI, USA) promoter tiling arrays covering promoter regions À3500 to þ 1000 nt were chosen for the analysis. Co-expression of C/EBPa was associated with 169 unique peaks of AR recruitment with a false discovery rate of p0.05 and 33 unique peaks of AR recruitment with a false discovery rate of p0.01 (annotated data provided in Supplementary Table 3) . The 169 peak sequences were submitted for analysis to the Trawler program, which identifies families of sequence motifs enriched in peak sequences compared with comparable background sequences (Ettwiller et al., 2007) . The family with the highest z-score (12.42) had several clusters that were identified as having significant matches to C/EBPa-binding motifs, as defined using the TRANSFAC and JASPAR databases. No enrichment for AREs was observed.
To test whether C/EBPa recruited AR to chromatin sites in a functional manner, several AR-associated peak genomic DNA sequences identified above were inserted upstream of the minimal promoter within the GAL4-TATA-Luc (pG5luc) reporter plasmid and tested in the AR-negative HeLa cells for their ability to enhance promoter activity in response to ectopic AR. Among the top 25 peaks, 10 peak sequences were selected, based on the ease of PCR amplification from genomic DNA and subcloning into the pG5luc reporter plasmid. In all, six of the sequences supported C/EBPa-dependent promoter activation by AR (Figures 7a-c) ; one of the sequences also showed C/EBPa-independent activation by AR (Figure 7c ), suggesting the presence of an additional tethering mechanism for AR within this sequence. Thus, the ChIP-chip peaks identified above include functional target sites of C/EBPa-dependent transcriptional activity of AR. It is possible that the peak sequences that did not give a functional response were limited by the promoter context. Androgen receptor (AR) upregulates the peroxisome proliferator-activated receptor-g (PPARg) gene from a CCAAT enhancer binding protein (C/EBP)-dependent AR recruitment site in the first intron By inspection of genes that showed both C/EBPadependent AR recruitment and C/EBPa-dependent gene activation by AR, the PPARg gene was identified as a direct target gene with an obvious physiological significance in prostate tissue. A site of C/EBPadependent recruitment of AR was identified in the first intron of the PPARg gene, at þ 257 to þ 616 nt. This region contained two C/EBP elements. A genomic fragment spanning the PPARg promoter and including this intronic region (À343 to þ 616 nt) was inserted upstream of a luciferase reporter gene in the pGL3 basic plasmid and tested in the AR-negative HeLa cells. As observed in Figure 8 , the promoter was activated by ectopic AR in a manner that was enhanced by ectopic C/EBPa; AR and C/EBPa could not activate the promoter construct in which the region of AR recruitment mapped by ChIP-chip (À343 to þ 616 nt) was deleted (Figure 8 ).
Discussion
The positive regulation of the transcriptional activity of AR by C/EBPa elucidated in this study, together with the negative regulation of AR activity by C/EBPa reported previously (Chattopadhyay et al., 2006) , reveal a unique bimodal association between two DNAbinding transcription factors that also interact reciprocally as co-regulators of each other. This type of interaction enables a switch in the gene regulatory pattern of the one transcription factor coincident with co-expression of the second. The exact nature of this interaction depends on the target promoter context, specifically the occurrence and configuration of DNA elements that bind either AR or C/EBPa. The association of AR with an ARE is ligand dependent and in this context, C/EBPa binds to AR as a corepressor; in contrast, the binding of C/EBPa to a C/EBP element and its recruitment of AR is entirely independent of ligand (barring ligand dependence for nuclear translocation of AR), resulting in promoter activation through further recruitment of AR co-activators. When target genes contain non-interacting ARE and C/EBP elements at distinct sites in their promoter regions, recruitment of AR at the C/EBP element leads to gene activation in a manner that is not influenced by events at the ARE site; in such promoters, androgen-dependent gene activation can occur through the ARE in the absence of C/EBPa. Inhibition of ARE-mediated gene activation has been attributed to competition between C/EBPa and coactivators for binding to AR (Chattopadhyay et al., 2006) ; however, it may be noted here that recruitment of AR at C/EBP elements, as shown in this study, would also predict inhibition of classical androgen target genes through sequestering of AR at non-classical target promoters by C/EBPa. In the normal prostate, both ligand-dependent and ligand-independent mechanisms of target gene interactions of AR must depend on androgen for translocation of the receptor to the nucleus. On the other hand, in hormone refractory prostate tumors, in which AR is localized in the nucleus independent of hormone, C/EBPa-mediated gene activation by AR would be entirely independent of hormone.
Although androgens are necessary for the growth and maintenance of the normal prostate and for prostatic hyperplasia, none of these processes have been linked with an alteration in the hormonal status. Therefore, androgens have a permissive role in prostate physiology in a manner that is regulated by other factors. In this context, the actions of C/EBPa and its interactions with AR are particularly significant. The diversity of gene regulatory patterns allowed by the AR-C/EBPa interactions adds to the independent activities of the two proteins, offering a significant physiological advantage in the development and function of the prostate. AR is necessary for supporting virtually all aspects of prostate physiology, but C/EBPa, a strongly antiproliferative protein, is only expressed in the nucleus of prostate epithelial cells beginning at the time of prostate maturation when it may be expected to inhibit the classical mechanism of gene activation by androgen. Whereas negative regulation of androgen signaling by C/EBPa may be needed to inhibit androgen-stimulated growth, alternate mechanisms of gene activation by androgen could be simultaneously facilitated by C/EBPa, appropriately redirecting androgen signaling to support its other functions. Consistent with this view, gene ontology analysis indicated a broad range of functions for the direct and indirect target genes of AR-C/EBPa. The physiological significance of gene coregulation by AR and C/EBPa is also illustrated by the specific example shown above of the upregulation of the PPARg gene; PPARg is expressed in prostate tissues, is antiproliferative and is a prostate tumor suppressor (Paltoo et al., 2003; Han and Roman, 2007) , in keeping with the known physiological effects of C/EBPa. This study has elucidated in detail the unique characteristics of a novel molecular mechanism of interaction between AR and C/EBPa and established the prevalence of these interactions in regulating androgen-induced gene expression patterns. It must be Figure 4 Mapping the protein domains of androgen receptor (AR) and CCAAT enhancer binding protein-a (C/EBPa) required for their interaction in the context of DNA-bound C/EBPa. (a) HeLa cells were transfected with GAL4-C/EBPa or Gal4 expression plasmid together with an expression plasmid for either VP16 or VP16 fusion proteins with the full-length AR (VP16-AR), AR with its N-terminal amino acids 1-37 deleted (VP16-delAR(N)), the AB domains of AR (VP16-AB), the CD domains of AR (VP16-CD), the E domain of AR (VP16-E) or the CDE domains of AR (VP16-CDE). The cells were co-transfected with the Gal4-TATA-Luc reporter. At 48 h after transfection, the cells were harvested to measure luciferase activity. (b) HeLa cells were transfected with an expression plasmid for either Gal4, the Gal4 fusion protein GAL4-C/EBPa(2-217) or GAL4 fusion proteins with various portions of C/EBPa polypeptide, as illustrated in the figure. The cells were co-transfected with the AR expression plasmid or vector control together with the Gal4-TATA-Luc promoter construct. The cells were treated with testosterone (10 nM) for the duration of the transfection (48 h) after which they were harvested for luciferase assays. The values are plotted as the fold increase in promoter activity relative to the values in the absence of AR. The western blot shows the relative expression levels of the fusion proteins by probing with antibody to GAL4. (c) HeLa cells were transfected with expression plasmids for C/EBPa or its mutant forms containing either an internal deletion of amino acids 146-156 or mutation of R154 to A. The cells were co-transfected with the AR expression plasmid or vector control together with the (C/EBP) 3 -TATA-Luc promoter construct. The cells were treated with testosterone (10 nM) for the duration of the transfection (48 h) after which they were harvested for luciferase assays. The western blot shows the relative expression levels by probing with antibody to C/EBPa. For panels a-c, the P-values for the differences noted in the text were o0.001.
noted that the profound effects of AR on the growth, differentiation and maintenance of the prostate are associated with a broad and complex (direct and indirect) transcriptional regulation, and it has been virtually impossible to assign specific functional groups of ultimate target genes of AR to the regulation of specific aspects of prostate physiology (Thomson and Marker, 2006) . Such correlations are further confounded by the fact that even after terminal differentiation, the prostatic epithelium constantly undergoes apoptosis and androgen-dependent regeneration. Therefore, the extensive nature of the influence of C/EBPa on the AR-regulated gene expression profile in LNCaP cells should, of itself, be taken as an indicator of a profound physiological role of C/EBPa in androgen regulation of prostate physiology.
Direct target gene activation by tethering to DNAbound transcription factors, such as Sp family proteins and activator protein-1, has been well established for the estrogen receptor (Jakacka et al., 2001; Safe and Kim, 2004) . AR is known to repress gene activation by activator protein-1 and nuclear factor-kB (RelA) but this seems to occur principally through sequestration of limiting amounts of the co-activator, CREB-binding protein (Aarnisalo et al., 1998; Frnsdal et al., 1998) . Tethering mechanisms have not been adequately elucidated for AR, notwithstanding a report that in myoblasts, AR activates the skeletal a-actin gene through its recruitment to the target promoter by serum response factor (Vlahopoulos et al., 2005) . As elucidated in this study, C/EBPa-dependent direct gene activation by AR is a clear example of tethering of AR to its target genes. Interestingly, this mechanism of transcriptional activation by AR occurs independently of hormone and is insensitive to a classical androgen antagonist. The degree of promoter activation by AR through association with DNA-bound C/EBPa was not diminished in a dimerization mutant of the receptor, indicating that the ligand-independent gene activation by AR through tethering to C/EBPa does not involve AR dimerization. The results represent the first detailed characterization of a tethering mechanism that supports the transcriptional activity of AR and that further, is independent of ligand.
Androgen receptor has a predominantly nuclear localization in hormone-refractory prostate cancer cells that are 'truly' independent of androgen. However, hormone-independent localization of AR in the nucleus will not result in ligand-independent activation through classical AREs; therefore, in the absence of hormone, AR-dependent growth must be supported by alternate modes of association of the receptor with its target genes, rather than by binding to its classical response elements (Jia and Coetzee, 2005) (Gonit et al., publication pending). C/EBPa frequently manifests in clinical prostate cancer similar to a variety of other tumors (Sundfeldt et al., 1999; Zhang et al., 2008 ; Oncomine microarray data repository, http://www.oncomine.org/) in which the cellular contexts may be expected to attenuate or overcome its antiproliferative effects (Wang et al., 2004; Wang and Timchenko, 2005) . C/EBPa-mediated trans-activation by AR in prostate cancer could therefore represent a significant aspect of AR function that is both independent of androgen and refractory to anti-androgen therapy. Figure 5 The effect of disrupting androgen receptor (AR) dimerization on the ability of CCAAT enhancer binding proteina (C/EBPa) to recruit AR. (a) HeLa cells were transfected with GAL4-C/EBPa or Gal4 expression plasmid together with an expression plasmid for VP16, VP16-AR or VP16-delAR(N) (deletion of amino acids 1-37). The cells were co-transfected with either Gal4-TATA-Luc or ARE-TATA-Luc. The cells were treated with testosterone (10 nM) or vehicle for the duration of the transfection (48 h) after which they were harvested for luciferase assays. The luciferase activities are plotted as the percentage of the maximal activity for each promoter construct. (b) HeLa cells were transfected with expression plasmid for Gal4 or GAL4 fused to AR containing only its CDE domains (GAL4-AR(CDE)) together with an expression plasmid for VP16, VP16-AR or VP16-delAR(N). The cells were co-transfected with either Gal4-TATA-Luc. The cells were treated with testosterone (10 nM) for the duration of the transfection (48 h) after which they were harvested for luciferase assays. The western blot shows the relative levels of VP16-AR and VP16-delAR(N) probed with antibody to AR. For panels a and b, the P-values for the differences noted in the text were o0.001. The combined effect of androgen receptor (AR) and CCAAT enhancer binding protein-a (C/EBPa) on global gene regulation. (a, c) LNCaP cells were transfected by nucleofection with either C/EBPa or vector. After 48 h, the cells were treated with either R1881(1 nM) or vehicle for 6 h. The cells were then harvested either for western blot analysis using antibody to AR or C/EBPa (a) or to obtain total RNA (c). In panel c, the mRNA profile was determined using replicate samples by Affymetrix microarray analysis and genes that were induced Xtwofold by R1881 in 6 h were selected; the data are plotted to show the effect of ectopic C/EBPa on the fold activation by R1881 of each gene; a value of 1 on the y axis indicates that R1881 stimulation was unaffected by C/EBPa. (b, d) LNCaP cells were transfected by nucleofection with C/EBPa or vector. After 24 h, the cells were infected with AR short hairpin RNA (shRNA) lentivirus or non-target control lentivirus; the cells were then grown in fresh hormone-free media. The cells were then treated for 48 h with either vehicle or R1881 (1 nM) as shown in (b). The cells were harvested at 72 h after nucleofection for either western blot analysis (b) or to obtain total RNA (d). In panel d, the mRNA profile was determined using replicate samples by Affymetrix microarray analysis; genes whose expression was unaffected by R1881/AR were selected; the data are plotted to show the increase in expression in the presence of R1881 þ AR þ C/EBPa compared with C/EBPa alone.
Materials and methods

Chemicals and reagents
Dulbecco's minimum essential medium, RPMI 1640, sodium pyruvate and penicillin/streptomycin/l-glutamine stock mix were purchased from Life Technologies, Inc. (Carlsbad, CA, USA); fetal bovine serum (FBS) and charcoal-stripped FBS (CS-FBS) were from Invitrogen (Carlsbad, CA, USA). ) were transfected with either a minimal promoter-luciferase reporter (pG5luc) or pG5luc in which the indicated genomic DNA fragments were inserted upstream of the minimal promoter. The chromosomal locations of the insert sequences are indicated on the x axis. The cells were co-transfected with an expression plasmid for AR (200 ng) or vector control and/or C/EBPa (50 ng) expression plasmid or vector control for 48 h. The cells were treated with testosterone (10 nM) or vehicle for the last 12 h of the transfection and harvested for luciferase assay. The relative promoter activities are plotted as the ratio to that of the corresponding promoter in the absence of AR and ectopic C/EBPa. The data for the different promoter constructs are plotted in a-c. For a-c, the P-values for the differences noted in the text were o0.001.
C/EBPa and androgen receptor signaling J Zhang et al purchased from Santa Cruz Biotechnologies (Santa Cruz, CA, USA). Peroxidase or fluorescein isothiocyanate-conjugated secondary antibodies were from Vector Laboratories (Burlingame, CA, USA). Cell Line Nucleofector Kits (R) were purchased from Amaxa Biosystems (Cologne, Germany). Custom oligonucleotide primers were from Life Technologies. Lipofectamine 2000 reagent was from Invitrogen. C/EBPa small interfering RNA (siRNA; s2888) and control siRNA were purchased from Ambion (Branchburg, NJ, USA). Vent DNA polymerase was purchased from New England Biolabs (Beverly, MA, USA). Custom oligonucleotide primers were from Integrated DNA Technologies (Coralville, IA, USA). The reagents for reverse transcription-PCR and real-time PCR were purchased from Applied Biosystems (Branchburg, NJ, USA).
DNA constructs and expression plasmids
Construct design used either natural restriction sites or restriction sites created by PCR using Vent DNA polymerase (New England Biolabs) and custom oligonucleotides (Integrated DNA Technologies). GAL4-TATA-Luc plasmid (pG5luc) and expression plasmid for VP16 and Gal4 were purchased from Promega (CheckMate Mammalian Twohybrid System). ARE-TATA-Luc, (C/EBP) 3À TATA-luc and (C/EBP) 3 -ARE-TATA-luc were made by cloning appropriate annealed oligos with the addition of KpnI(5 0 ) and NheI(3 0 ) terminal restriction sites into the large segment of GAL4-TATA-Luc digested by KpnI and NheI. A high-affinity ARE, 5 0 -AGTACGTGATGTTCT-3 0 (Schoenmakers et al., 2000) was inserted upstream of the TATA box. (C/EBP) 3 is a threetandem repeated C/EBP consensus element, (TGCAGA TTGCGCCAATCTGCA) 3 ; the sequence underlined is the central binding motif. delC/EBP-TATA-Luc was made by deleting the GAL4 element from GAL4-TATA-Luc with KpnI and NheI digestion and then re-ligating the reporter after blunting of both restriction ends. The Renilla luciferase transfection control was the pRL-null plasmid from Promega. Gal4 fusions of various deleted versions of C/EBPa activation domain, that is, C/EBPa(107-217), C/EBPa(121-217), C/ EBPa(139-217) and C/EBPa(156-217), were all constructed by PCR using Gal4-C/EBPa(6-217) plasmid as the template and the appropriate primers and subcloned at EcoRI (upstream) and XbaI (downstream) sites in a vector for expressing Gal4 fusions (pSG424) (Sadowski and Ptashne, 1989) . To test the functionality of chromatin sites mapped by ChIP-chip analyses, genomic DNA fragments were amplified using PCR, digested with the appropriate restriction enzymes and cloned upstream of the minimal promoter in the pG5luc plasmid in place of the GAL4 element. The PPARg promoter plasmids were constructed by amplifying genomic DNA fragments by PCR using Pfu Turbo Polymerase followed by insertion upstream of the luciferase reporter in the pGL3-basic vector (Promega). The recombinant plasmids were amplified in Escherichia coli strain XL1 Blue and purified using the Qiagen plasmid kit (Qiagen, Chatsworth, CA, USA). The entire cloned DNA sequence in each construct was verified using automated DNA sequence analysis. The AR-specific short hairpin RNA (shRNA) and non-targeting shRNA control in the lentiviral expression vector, pLKO.1 puro, were purchased from SigmaAldrich (St Louis, MO, USA). The shRNA sequence for AR is: Cell culture and transfection HeLa (American Type Culture Collection) cells were cultured in Dulbecco's minimum essential medium supplemented with FBS (10%), penicillin (100 unit/ml), streptomycin (100 mg/ml) and l-glutamine (2 mm). LNCaP cells (American Type Culture Collection) were maintained in RPMI 1640 medium supplemented with FBS (10%), sodium pyruvate (1 mm), penicillin (100 unit/ml), streptomycin (100 mg/ml) and L-glutamine (2 mM). To obtain hormone depletion, in all the experiment, HeLa cells were grown in phenol red-free media supplemented with charcoal-stripped FBS (5% v/v), L-glutamine (2 mM), insulin (2 mg/ml) and transferrin (40 mg/ml) for 72 h. HeLa cells were transfected with DNA constructs in six-well plates (Corning, New York, NY, USA) using FuGENE 6 (Roche Diagnostics), according to the manufacturer's protocol. Normally, 500 ng reporter and 25-100 ng of each expression plasmid were used where not specially indicated. LNCaP cells were nucleofected with Amaxa nucleofector Kit R (Amaxa), according to the manufacturer's protocol. A total of 2 mg of expression plasmid was used in the nucleofection. Immediately after the nucleofection, the cells were transferred to phenol red-free RPMI 1640 supplemented with CS-FBS (5% v/v), sodium pyruvate (1 mM), L-glutamine (2 mM), insulin (2 mg/ml) and transferrin (40 mg/ml). Transfection efficiency and promoter specificity were controlled using the pRL-null plasmid expressing Renilla luciferase and measurement of Renilla luciferase activity in the cell lysates. In the gene expression profiling experiments, transfection efficiency was determined using flow cytometry to determine the proportion of cells that expressed co-transfected green fluorescent protein expression plasmid.
Luciferase assay
The procedure for the preparation of cell lysates of transfected cells and the use of the Firefly luciferase assay system were as described (Shatnawi et al., 2007) . The activity of co-transfected Renilla luciferase (transfectyion control) was also measured as described (Shatnawi et al., 2007) . All luciferase assays were performed at least in triplicate.
Western blots
Cell lysates were prepared and analysed using western blot as described (Shatnawi et al., 2007) . Gene silencing by infection with short hairpin RNA (shRNA) lentivirus The AR shRNA vector or the non-targeting shRNA control vector was packaged into lentivirus. The virus particles were generated by transfecting 293FT cells using Lipofectamine 2000 reagent. Lentivirus was harvested from the supernatant at 48 h and 72 h after transfection. LNCaP cells were plated in 12-well plates the day before infection (1.5 Â 10 5 cells per well); 0.5 ml virus supernatant combined with polybrene (800 mg/ml) was used for the infection of each well together with 0.5 ml media (RPMI 1640 media containing 10% heat-inactivated FBS, 2 mM L-glutamine and 1 mM sodium pyruvate); after 4-5 h, the infection procedure was repeated. At approximately 4-5 h after the second infection, the cells were placed in fresh media.
Immunofluorescence and confocal microscopy HeLa cells (2 Â 10 5 ) were plated in chamber slides and transfected at 50% confluence with different doses of AR expression plasmid (10 ng, 50 ng, 100 ng and 200 ng) or vector and treated with either testosterone (10 nM) or vehicle for the duration of the transfection (48 h). The cells were washed twice with phosphate-buffered saline PBS (2 mM potassium dihydrogen phosphate, 10 mM disodium phosphate, 2.7 mM potassium chloride and 137 mM sodium chloride) and were fixed with freshly prepared 3.7% paraformaldehyde in PBS for 10 min at room temperature. The cells were then permeabilized in PBS containing 0.1% bovine serum albumin and 0.3% Triton X-100 for 5 min at room temperature. The cells were then washed and blocked with PBS containing 5% serum and 0.2% Triton X-100 at room temperature for 1 h. The cells were incubated overnight at 4 1C with the antibody to AR in a dilution of 1:50. After washing thrice with PBS containing 5% serum and 0.2% Triton X-100, the cells were incubated with bovine anti-rabbit immunoglobulin G conjugated to fluorescein isothiocyanate for 1 h in the dark at room temperature in a dilution of 1:100. After the final wash, the cells were incubated for 2 min in 4,6-diamidino-2-phenylindole, washed thrice and mounted using Vectashield (Burlingame, CA, USA) mounting medium. Images were acquired using the Leica TCS SP5 Broad band confocal microscope system (Leica, Wetzlar, Germany). The acquisition settings were kept constant between specimens and a negative control sample incubated with normal immunoglobulin G primary antibody was used to adjust for background. Sub-cellular localization of AR was examined by acquiring 10 optical sections using Â 40 oil immersion with additional Â 3.5 optical zoom. The images were compiled as projections using the Leica LAS software package. The total amount of fluorescence in the cell and the amount of fluorescence localized in the nucleus were quantified using the LASAF software (Wetzlar, Germany).
mRNA profiling
The Affymetrix DNA microarray analysis was performed as a full service global gene expression study at the transcriptional profiling core facility of the Cancer Institute of New Jersey. Total RNA samples were used to generate labeled cRNAs, which were hybridized to human U133 Plus2.0 Affymetrix microarrays. The expression data were analysed initially using Affymetrix GeneChip Operating Software to create CEL files. The CEL files were imported into the Bioconductor program affylmGUI (Wettenhall et al., 2006) . The probe set level intensities were quantified and normalized using robust multiarray averaging and quantile normalization. Differential expression between treatments was determined using the limma linear modeling method, and the significance of differences were ranked by the moderated t-statistic.
Chromatin immunoprecipitation-DNA microarray chip (ChIP-chip) analyses LNCaP cells were nucleofected with either 2 mg of C/EBPa or the corresponding empty vector for 48 h, and then the cells were treated for 2 h with either R1881 (1 nM) or vehicle and subjected to ChIP as described (Shatnawi et al., 2007) using anti-AR antibody. The recruitment of AR to the major ARE enhancer region of the PSA promoter (À4366 to À3874 nt) was measured using real-time PCR. An irrelevant target sequence within the downstream coding region was used as a negative control. The primers and TaqMan probe used to target the PSA ARE enhancer region were: 5 0 -GCCTGGATCTGAG AGAGATATCATC-3 0 (forward primer), 5 0 -ACACCTTTT TTTTTCTGGATTGTTG-3 0 (reverse primer) and 56FAM-TGCAAGGCCTGCTTTACAAACTTCC-36TAM (probe). The primers and TaqMan probe used to target the irrelevant coding sequence of PSA were: 5 0 -CACACCCGCTCTACG ATATGA (forward primer), 5 0 -GAGCTCGGCAGGCTCT GA-3 0 (reverse primer) and 56-FAM-CTCCAGC CCG ACCTCATGCTGCT-36TAM (probe). The immunoprecipitated DNA samples (10 ng) that were validated for PSA as well as corresponding input DNA were amplified using the Sigma GenomePlex WGA2 kit (Sigma-Aldrich) to generate at least 4 mg of DNA for chip analysis using the Nimblegen 385 K H18 tiling array platform. The labeling and hybridization of DNA samples were performed by NimbleGen Systems, Inc (Madison, WI, USA). As described in the Nimblegen website, the data were analysed using the Nimblescan software to identify peaks by searching for four or more probes whose signals were above the specified cutoff values, ranging from 90 to 15%, using a 500-bp sliding window. The cutoff values are a percentage of a hypothetical maximum, which is the mean þ 6 s.d. The ratio data were then randomized 20 times to assign a false discovery rate score. A false discovery rate of p0.05 was considered to be highly indicative of binding sites for AR.
Statistical analyses
All experimental values in Figures 1, 2, 3, 4 and 6 are presented as mean±s.d. The statistical significance of differences (Pvalue) between values being compared was determined using analysis of variance. In all cases, the differences noted in the text are reflected by a P-value of o0.001.
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